{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:46:58Z","timestamp":1789739218544,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejca.2024.115122","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:04:25Z","timestamp":1731704665000},"page":"115122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies"],"prefix":"10.1016","volume":"216","author":[{"given":"Vincent","family":"Ribrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Mei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Beltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Suenaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiruvamoor","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115122_bib1","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/ncomms4127","article-title":"The central role of EED in the orchestration of polycomb group complexes","volume":"5","author":"Cao","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2024.115122_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2021.1841167","article-title":"Targeting PRC2 for the treatment of cancer: an updated patent review (2016\u20132020)","volume":"31","author":"Dockerill","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ejca.2024.115122_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.115122_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer \u2013 biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib5","first-page":"3267","article-title":"Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma","volume":"10","author":"Zhu","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ejca.2024.115122_bib6","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/1568026621666210920154942","article-title":"Embryonic ectoderm development (EED) as a novel target for cancer treatment","volume":"21","author":"Cook","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ejca.2024.115122_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nchembio.2306","article-title":"The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ejca.2024.115122_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ejca.2024.115122_bib9","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1021\/acs.jmedchem.1c02148","article-title":"Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies","volume":"65","author":"Huang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2024.115122_bib10","first-page":"1","article-title":"Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment","author":"Zhang","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejca.2024.115122_bib11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115122_bib13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib14","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1200\/JCO.2007.12.1012","article-title":"Translation of innovative designs into phase I trials","volume":"25","author":"Rogatko","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774509356002","article-title":"Summarizing historical information on controls in clinical trials","volume":"7","author":"Neuenschwander","year":"2010","journal-title":"Clin Trials"},{"key":"10.1016\/j.ejca.2024.115122_bib16","series-title":"A Bayesian Industry Approach to Phase I Combination Trials in Oncology","author":"Neuenschwander","year":"2014"},{"key":"10.1016\/j.ejca.2024.115122_bib17","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03; 2010. \u3008https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm\u3009."},{"key":"10.1016\/j.ejca.2024.115122_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2024.115122_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib20","article-title":"An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma","author":"Izutsu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2024.115122_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115122_bib22","first-page":"589","article-title":"EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population","volume":"53","author":"Zhou","year":"2014","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ejca.2024.115122_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.115122_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2024.115122_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.115122_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clbc.2017.09.009","article-title":"Epigenetic pathways offer targets for ovarian cancer treatment","volume":"18","author":"Gyparaki","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2024.115122_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3892\/or.2015.4421","article-title":"ARID1A gene mutation in ovarian and endometrial cancers (review)","volume":"35","author":"Takeda","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2024.115122_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061528","article-title":"Feature reviews of the molecular mechanisms of nasopharyngeal carcinoma","volume":"11","author":"Liao","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2024.115122_bib29","unstructured":"Novartis AG . Data on file; 2016."},{"key":"10.1016\/j.ejca.2024.115122_bib30","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.4161\/cc.5.16.3222","article-title":"Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer","volume":"5","author":"Berezovska","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2024.115122_bib31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1186\/1471-2407-14-994","article-title":"The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters","volume":"14","author":"Ngollo","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.115122_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Culig","year":"1999","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:50:36Z","timestamp":1740412236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0959804924017295"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115122","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115122"}}